Business Description
Eliem Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US28658R1068
Description
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its main drug candidate is ETX-155 for major depressive disorder (MDD) and focal onset seizures (FOS).
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 306.01 | |||||
| Equity-to-Asset | 0.97 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -13.9 | |||||
| 3-Year EPS without NRI Growth Rate | -9.4 | |||||
| 3-Year FCF Growth Rate | 14.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 95.75 | |||||
| 9-Day RSI | 91.26 | |||||
| 14-Day RSI | 88.02 | |||||
| 6-1 Month Momentum % | 7.36 | |||||
| 12-1 Month Momentum % | -19.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 38.92 | |||||
| Quick Ratio | 38.92 | |||||
| Cash Ratio | 37.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -33.4 | |||||
| Shareholder Yield % | 0.04 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -30.52 | |||||
| ROA % | -29.43 | |||||
| ROIC % | -706.31 | |||||
| ROC (Joel Greenblatt) % | -4815.28 | |||||
| ROCE % | -34.95 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.61 | |||||
| Price-to-Tangible-Book | 2.61 | |||||
| EV-to-EBIT | -4.35 | |||||
| EV-to-EBITDA | -4.35 | |||||
| EV-to-FCF | -8.5 | |||||
| Price-to-Net-Current-Asset-Value | 2.62 | |||||
| Price-to-Net-Cash | 2.71 | |||||
| Earnings Yield (Greenblatt) % | -22.99 | |||||
| FCF Yield % | -7.32 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ELYM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eliem Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.31 | ||
| Beta | 0 | ||
| Volatility % | 160.52 | ||
| 14-Day RSI | 88.02 | ||
| 14-Day ATR ($) | 0.925619 | ||
| 20-Day SMA ($) | 4.77925 | ||
| 12-1 Month Momentum % | -19.01 | ||
| 52-Week Range ($) | 2.34 - 11.55 | ||
| Shares Outstanding (Mil) | 27.72 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eliem Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Eliem Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Eliem Therapeutics Inc Frequently Asked Questions
What is Eliem Therapeutics Inc(ELYM)'s stock price today?
The current price of ELYM is $10.15. The 52 week high of ELYM is $11.55 and 52 week low is $2.34.
When is next earnings date of Eliem Therapeutics Inc(ELYM)?
The next earnings date of Eliem Therapeutics Inc(ELYM) is 2024-05-10 Est..
Does Eliem Therapeutics Inc(ELYM) pay dividends? If so, how much?
Eliem Therapeutics Inc(ELYM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers